Kourouklis C, Christensen O, Augoustakis D
Curr Med Res Opin. 1976;4(6):422-31. doi: 10.1185/03007997609111998.
Bumetanide, a new diuretic exerting its major effect on the ascending limb of the loop of Henle, was evaluated in 20 patients with congestive heart failure. Dosage ranged from 1 mg to 3 mg daily depending on the patient's condition. The results after 3 and 8 days' treatment showed that bumetanide caused a significant diuresis, an increased excretion of sodium, potassium and chloride, and a comparable fall in the serum levels of these electrolytes. Changes in electrolyte levels were directly related to the dose of the drug. The resultant hypochloraemia was accompanied by a slight metabolic alkalosis. A comparative crossover study between placebo, bumetanide and frusemide using equipotent doses was performed in 10 patients. Both drugs had a similar effect upon water excretion and the serum and urinary electrolytes.
布美他尼是一种主要作用于髓袢升支的新型利尿剂，对20例充血性心力衰竭患者进行了评估。根据患者病情，剂量范围为每日1毫克至3毫克。3天和8天治疗后的结果表明，布美他尼引起显著的利尿作用，钠、钾和氯的排泄增加，这些电解质的血清水平也相应下降。电解质水平的变化与药物剂量直接相关。由此导致的低氯血症伴有轻度代谢性碱中毒。对10例患者进行了安慰剂、布美他尼和呋塞米等剂量的比较交叉研究。两种药物对水排泄以及血清和尿液电解质的作用相似。
